Stockholm - Delayed Quote SEK

BioInvent International AB (publ) (BINV.ST)

31.00

+0.60

+(1.97%)

At close: 5:29:57 PM GMT+2

BioInvent Presents Additional CTCL Phase 2a Data for BI-1808 Monotherapy at EHA 2025

Data from the cutaneous T-cell lymphoma (CTCL) cohort demonstrate promising clinical activity that correlates with strong immune activation One complete response (CR), three partial responses (PR), and four stable diseases (SD) achieved as of Feb ...

ACCESS Newswire 6 days ago

BINV.ST
+1.97%
BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma

Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three partial responses (PR), and three stable disease (SD) as best clinical response in the first eight patients evaluated Results ...

ACCESS Newswire 6 days ago

BINV.ST
+1.97%
BioInvent to Participate in Upcoming Investor Conferences

LUND, SE / ACCESS Newswire / May 5, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, ...

ACCESS Newswire 15 days ago

BINV.ST
+1.97%
Resolutions at BioInvent's Annual General Meeting 2025

LUND, SWEDEN / ACCESS Newswire / April 29, 2025 / The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) resolved to re-elect the Board members Natalie Berner, Kristoffer Bissessar, Thomas Hecht, Leonard ...

ACCESS Newswire 21 days ago

BINV.ST
+1.97%
BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma

LUND, SE / ACCESS Newswire / April 29, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, ...

ACCESS Newswire 21 days ago

BINV.ST
+1.97%
BioInvent International AB: Interim Report January - March 2025

LUND, SE / ACCESS Newswire / April 29, 2025 / BioInvent International (STO:BINV) "The first quarter of 2025 was a highly productive period across clinical development, regulatory milestones, and strategic partnerships - positioning us for strong momentum ...

ACCESS Newswire 21 days ago

BINV.ST
+1.97%
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

LUND, SWEDEN / ACCESS Newswire / April 8, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, ...

ACCESS Newswire last month

BOVNF
BioInvent International AB Publishes Annual Report 2024

LUND, SE / ACCESS Newswire / April 4, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory antibodies for cancer immunotherapy, ...

ACCESS Newswire last month

BOVNF
Notice to Annual General Meeting in BioInvent International AB

LUND, SE / ACCESS Newswire / March 25, 2025 /BioInvent International (STO:BINV) The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 29 April 2025 ...

ACCESS Newswire last month

BOVNF
BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum

LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, ...

ACCESS Newswire last month

BOVNF
BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma

LUND, SE / ACCESS Newswire / March 20, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, ...

ACCESS Newswire last month

BOVNF
BioInvent International AB: Year-End Report January 1 - December 31, 2024

LUND, SWEDEN / ACCESS Newswire / February 27, 2025 / BioInvent International (STO:BINV) "2024 was a year with several exciting developments reported from across our broad portfolio of clinical programs. We now have two Phase 2 and four Phase 1 trials ...

ACCESS Newswire 2 months ago

BOVNF
Invitation to Presentation of BioInvent's Year-end Report 2024

LUND, SE / ACCESS Newswire / February 25, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the Year-end report 2024 on February 27 at 4:00 pm CET. The report will ...

ACCESS Newswire 2 months ago

BOVNF
BioInvent Achieves ISO 26000 Verification, Highlighting Commitment to ESG and Transparency

LUND, SWEDEN / ACCESSWIRE / January 10, 2025 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory ...

ACCESS Newswire 4 months ago

BOVNF
BioInvent Announces Promising Data for BI-1910 as Single Agent from Phase 1 Study in Solid Tumors

LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV) BI-1910 single agent Phase 1 Part A dose escalation has been completed and reached a biologically active dose level. Data show stable disease as best clinical response ...

ACCESS Newswire 4 months ago

BOVNF
BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma

LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV) The first two patients enrolled in the Phase 2a study triplet arm combining BI-1206 with rituximab and Calquence® responded to treatment One complete response (CR) and ...

ACCESS Newswire 4 months ago

BOVNF
BioInvent Announces First Patient Enrolled in Phase 1b/2a Study of BI-1607 in Combination with Ipilimumab and KEYTRUDA (Pembrolizumab) in Patients with Unresectable or Metastatic Melanoma

Study to evaluate safety and anti-tumoral activity of anti-FcgRIIB antibody BI-1607 with anti-CTLA-4: ipilimumab, in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA)( anti-PD-1 therapy, KEYTRUDA® (pembrolizumab); initial data expected in ...

ACCESS Newswire 5 months ago

BOVNF
BioInvent Appoints Ashley Robinson as SVP Strategy & Finance to Lead US Expansion

LUND, SWEDEN and BOSTON, MA / ACCESSWIRE / December 3, 2024 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for ...

ACCESS Newswire 5 months ago

BOVNF
Exploring High Growth Tech Stocks This November 2024

As global markets show resilience with major U.S. indexes approaching record highs and smaller-cap indexes outperforming, investor sentiment remains cautiously optimistic amid geopolitical tensions and economic uncertainties. In this environment, identifying high-growth tech stocks requires a focus on companies that demonstrate strong fundamentals, innovative capabilities, and adaptability to evolving market conditions.

Simply Wall St. 5 months ago

BOVNF
BioInvent International AB: Interim Report January-September 2024

LUND, SWEDEN / ACCESSWIRE / October 31, 2024 / BioInvent International (STO:BINV) "Progress to date brings the company one step closer to addressing the needs for new treatment solutions for patients. As part of our Q3 report, we are today pleased ...

ACCESS Newswire 6 months ago

BOVNF

Performance Overview

Return	BINV.ST	OMX Stockholm 30 Index (^OMX)
YTD	-19.48%	+3.22%
1-Year	+4.91%	-2.63%
3-Year	-30.02%	+28.53%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioInvent International AB (publ) (BINV.ST)

BioInvent Presents Additional CTCL Phase 2a Data for BI-1808 Monotherapy at EHA 2025

BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma

BioInvent to Participate in Upcoming Investor Conferences

Resolutions at BioInvent's Annual General Meeting 2025

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma

BioInvent International AB: Interim Report January - March 2025

BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3

BioInvent International AB Publishes Annual Report 2024

Notice to Annual General Meeting in BioInvent International AB

BioInvent’s anti-TNFR2 antibody BI-1808 showcased at the 16th Annual T-Cell Lymphoma Forum

BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma

BioInvent International AB: Year-End Report January 1 - December 31, 2024

Invitation to Presentation of BioInvent's Year-end Report 2024

BioInvent Achieves ISO 26000 Verification, Highlighting Commitment to ESG and Transparency

BioInvent Announces Promising Data for BI-1910 as Single Agent from Phase 1 Study in Solid Tumors

BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma

BioInvent Announces First Patient Enrolled in Phase 1b/2a Study of BI-1607 in Combination with Ipilimumab and KEYTRUDA (Pembrolizumab) in Patients with Unresectable or Metastatic Melanoma

BioInvent Appoints Ashley Robinson as SVP Strategy & Finance to Lead US Expansion

Exploring High Growth Tech Stocks This November 2024

BioInvent International AB: Interim Report January-September 2024

Performance Overview